K Heran Darwin is at New York University Grossman School of Medicine and a regular columnist for EMBO reports.
Vaxcyte Inc.’s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 ...
PCV13 is linked to some additional benefit in the prevention of COVID-19 infection among adults who received at least 2 COVID-19 vaccine doses.
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PCVX), a clinical-stage vaccine innovation company ...
Vaxcyte’s market potential is driven by $13.3B TAM in pneumococcal vaccine market, with potential FDA approval by late 2026 ...
A GRAM Project study forecasts a sharp rise in deaths from antimicrobial resistance, predicting over 39 million lives lost by ...
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PCVX), a clinical-stage vaccine innovation company ...
Malaria and typhoid-conjugate vaccines are yet to be deployed ... could reduce levels of AMR — by lowering the chance of ...
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at https://investors.vaxcyte.com. A replay of the webcast will be available for ...
A landmark GRAM Project study of global antimicrobial resistance (AMR) burden over time forecasts a sharp rise in deaths, with 39 million lives lost ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback